openPR Logo
Press release

Creative Diagnostics Supports COVID-19 Testing with Antigen Lateral Flow Assay Development

01-12-2021 10:42 AM CET | Science & Education

Press release from: Creative Diagnostics

As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics now introduces COVID-19 Antigen Lateral Flow Assay Development, including the SARS-CoV-2 nucleoprotein antibody pair for rapid COVID-19 antigen assays to equip healthcare workers for rapid COVID-19 antigen detection. Additionally, Creative Diagnostics also offers SARS-CoV-2 antigen extraction buffer tubes that can be used as packing supplies for SARS-CoV-2 antigen extraction.

The global COVID-19 pandemic has created an urgent demand for accurate rapid point of care testing. Antigen-based assays are suitably inexpensive and can be rapidly mass-produced, but sufficiently accurate performance requires highly optimized antibodies and assay conditions. Creative Diagnostics team has tested hundreds of anti-nucleocapsid antibody pairs to recommend clients the best pair for further development of an LFA for SARS-CoV-2 Antigen.

SARS-CoV-2 antigen extraction buffer tubes are also designed by Creative Diagnostics experts to extract SARS-CoV-2 antigen from nasopharyngeal swab, which can be used as packing supplies for SARS-CoV-2 Rapid Antigen test development and production. It's noted that the slim tube design of these plastic tubes also reduces the need for the amount of extraction buffer, thereby increasing the concentration of the virus antigen in the sample and improving the positive detection rate of virus antigen.

"To better response to the pandemic, Creative Diagnostics remains focused on its mission to serve the life science community to achieve their mission faster. We'll continue to expand our COVID-19 test portfolio, and increase our accurate, convenient diagnostic testing offerings to help global scientists to address the growing COVID-19 threat." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.

"We know that many scientists are still diligently pursuing their research, particularly those focused on COVID-19, and to meet their growing needs, we've provided a series of additional SARS-CoV-2 related products and services to ensure that our customers have the supplies they need to continue their research programs. We are proud to support them in these efforts." said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.

If you want to know more information about SARS-CoV-2 related testing products or other coronavirus research materials, please contact Creative Diagnostics at 1-631-619-7922 or email to contact@creative-diagnostics.com.

45-1 Ramsey Road, Shirley, NY 11967, USA
Thomas Schmitt
contact@creative-diagnostics.com

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Diagnostics Supports COVID-19 Testing with Antigen Lateral Flow Assay Development here

News-ID: 2187822 • Views: 220

More Releases from Creative Diagnostics

ACE2 Products Are Available at Creative Diagnostics to Advance SARS-CoV-2 Resear …
With COVID-19 rapidly spreading globally, scientists all over the world are devoted to related researches, trying to find an effective vaccine or drug to stop this epidemic. Angiotensin-converting enzyme 2 (ACE2) is an integral membrane protein with considerable homologous to ACE, which belongs to the peptidase M2 family. In case of human coronaviruses SARS and HCoV-NL63 infections, ACE-2 serves as a functional receptor for the spike glycoprotein of both coronaviruses.

More Releases for Antigen

New HGH Saliva Antigen Covid Test gamechanger
An Austrian company HGH Disinfection und Cosmetique Gmbh, based in 9020 Klagenfurt created with a Korean partner a unique antigen salvia test unit which is so simple that anybody can use it. Till now mass testing was nasal stick by government and doctors. Now this new test unit can be used by everybody without a scarry stick in the nose and a result with 95% is ready in 10
p53 Antigen Modulators Therapeutics- Pipeline Analysis 2018 |
p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage. p53 antigen modulators helps in preventing cancer development through regulation of cell cycle and apoptosis. Download the sample report @ https://www.pharmaproff.com/request-sample/1195 Thus, new opportunities in cancer immunotherapy are expected to develop better drug candidates targeting p53, with complete understanding of interactions between p53 and the immune system, to avoid various
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Anti …
ReportsWorldwide has announced the addition of a new report title Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also
CancerTestis Antigen 1 (Autoimmunogenic CancerTestis Antigen NY ESO 1 or CancerT …
ReportsWorldwide has announced the addition of a new report title CancerTestis Antigen 1 (Autoimmunogenic CancerTestis Antigen NY ESO 1 or CancerTestis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) -
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Anti …
Market Research Hub (MRH) added a new research report to its vast database titled “Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Pipeline Review, H2 2017” targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion
B-Cell Maturation Antigen Targeted Therapies Market
Multiple myeloma is an incurable disease of plasma cells, which needs some intervention by clinical researchers. However, there have been recent success in developing such therapy that can be effective in hematologic malignancies such as chimeric antigen receptor CAR-T cell therapy, which is expected to be promising in cancer treatment. However, researchers have found little success in finding a specific target antigen under CAR T-cell therapies for treating multiple myeloma.